The United States Food and Drug Administration (US FDA) inspected Aurobindo Pharma Ltd's Unit VII, an oral manufacturing facility situated at Jedcherla, Hyderabad, from 2nd to 10th May 2022. At the end of the inspection, we have been issued a 'Form 483' with six observations. The Company will respond to the US FDA within the stipulated timeline and work closely with US FDA to close the observations. Shares of Aurobindo Pharma Limited was last trading in BSE at Rs. 603.05 as compared to the previous close of Rs. 614.35. The total number of shares traded during the day was 39817 in over 2429 trades. The stock hit an intraday high of Rs. 621.25 and intraday low of 600.00. The net turnover during the day was Rs. 24304391.00.

Website Created & Maintained by : Chennai Scripts West Mambalam, Chennai - 600 033, Tamil Nadu, India